GILD · CIK 882095
What Gilead Sciences, Inc. told the SEC could break it.
Gilead's register is defined by concentration. Its U.S. sales funnel through just three wholesalers — Cardinal Health (29% of total gross product sales), Cencora (21%), and McKesson — which together take about 90% of U.S. gross product sales, and its revenue leans heavily on one therapeutic franchise, HIV treatment and prevention, exposed to competition and generics. On the supply side, some of its products and materials are made or tested by only one supplier or at a single facility it may not be able to replace quickly. Looking ahead, a U.S. Section 232 pharmaceutical-import probe and a September 2025 plan to impose up to 100% tariffs on imported branded or patented drugs threaten its manufacturing costs and supply-chain resilience.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- three wholesalers ~90% of U.S. gross product sales (Cardinal Health 29%, Cencora 21%, McKesson)high
Historically ~90% of Gilead's U.S. gross product sales go to three large wholesalers — Cardinal Health (29% of total gross product sales), Cencora (21%) and McKesson (>10%) — each individually above the 10% threshold, an extreme distribution-channel concentration.
“approximately 90% of our gross product sales in the U.S. have been to three large wholesalers—Cardinal Health, Inc., Cencor”
SEC filing →As of 2026 - substantial revenue concentration in HIV productsmedium
Gilead receives a substantial portion of its revenue from products for the treatment and prevention of HIV infection and may be unable to sustain or grow those sales due to competition, generics, or inability to introduce new HIV medications.
“We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection.”
SEC filing →As of 2026
Sole-source dependency
- single-supplier / single-facility manufacturing for some products and materialshigh
Some of Gilead's products and the materials it uses are manufactured and/or tested by only one supplier or at only one facility, which it may not be able to replace in a timely manner on commercially reasonable terms, or at all.
“Some of our products and the materials that we utilize in our operations are manufactured and/or tested by only one supplier or at only one facility, which we may not be able to replace in a timely manner and on commercially reasonable terms, or at all.”
SEC filing →As of 2026
Regulatory & policy
- Sept 2025 threatened up-to-100% tariffs on imported branded/patented pharmaceuticals + Section 232 probemedium
A U.S. Commerce Department investigation into pharmaceutical/ingredient imports could lead to tariffs or import quotas; in September 2025 the administration announced plans to impose up to 100% tariffs on imported branded or patented pharmaceuticals (subject to exceptions), threatening Gilead's manufacturing costs and supply-chain resiliency.
“in September 2025, the U.S. Presidential administration announced plans to impose up to 100% tariffs on imported branded or patented pharmaceuticals, subject to certain exceptions.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“approximately 90% of our gross product sales in the U.S. have been to three large wholesalers—Cardinal Health, Inc., Cencor[a], ... McKesson Corporation”
Cited →“Cardinal Health, Inc. (“Cardinal Health”) 29 % 29 % 28 % Cencora, Inc. (“Cencora”) 21 % 21 % 22 % McKesson Corporation (“Mc”
Cited →“Collaboration revenue of $62.4 million and $30.0 million for the years ended December 31, 2025 and 2024, respectively, was derived from the Gilead collaboration.”
Cited →“Cardinal Health, Inc. (“Cardinal Health”) 29 % 29 % 28 % Cencora, Inc. (“Cencora”) 21 % 21 % 22 % McKesson Corporation (“Mc”
Cited →
Its suppliers
Johnson & Johnson (Janssen Sciences Ireland)
“Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). ... We retain a specified percentage of Janssen's share of revenues, including up to 30 % in major markets.”
Cited →“We recognized collaboration revenue from the Gilead Agreement of $7.1 million and $14.0 million during the years ended November 30, 2025 and 2024, respectively.”
Cited →“we entered into the Third Gilead Collaboration Agreement Amendment, which we determined was a change in scope and price of the arrangement”
Cited →“The Company partnered anito-cel with Kite Pharma, Inc., a Gilead company (Kite)”
Cited →“Upon passing $ 3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65 % for any revenues above the threshold for such calendar year. Reimbursements of R&D costs to or from Merck are recorded within Research and development expenses”
Cited →“Our only revenues have been derived from research collaboration arrangements with Vertex Pharmaceuticals Incorporated, or Vertex,, Sanofi and Gilead.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch